I'll research DexCom (DXCM) before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent earnings materials and the investor day transcript.Now let me review the Investor Day, recent stock performance, and news to round out the picture.Let me check for news around the pivotal ADA CONNECT trial readout (early June) and any recent analyst/competitor context.Let me pull the prior-year Q2 comp for context on the YoY setup.I have what I need. Let me quickly run the key setup math before writing.Here is the earnings preview.
DexCom heads into Q2 with real momentum — a beat-and-raise Q1, a well-received May Investor Day, and a mid-year rally back near the highs — but the print itself is likely to take a back seat to two things investors actually care about: (1) the trajectory of U.S. new-patient starts / share gains, and (2) any incremental read on the Type 2 non-insulin (T2NIT) coverage cycle, especially CMS. This is a "quality-of-growth and catalysts" quarter more than a "beat the number" quarter.
Stock. DXCM is around $75, up ~13% YTD and up ~31% off its late-April low of ~$57.6. The two clear step-ups this year came off the May 14 Investor Day (shares jumped from ~$58 to ~$71 in a week) and the June ADA CONNECT trial readout (~$73 → ~$78 into early June), before drifting back and recovering into the print. Translation: a fair amount of good news — the LRP, the ADA data, the capital-return message — is already in the stock, which raises the bar for the quarter.
What management has already told us. On the Q1 call (April 30) DexCom reaffirmed FY26 revenue of $5.16–5.25B (11–13% growth) and raised non-GAAP operating margin to 23–23.5% and adjusted EBITDA margin to 31–31.5%, while holding gross margin at 63–64%. Q1 itself was strong: revenue $1.192B (+15% reported / +12% organic), gross margin 63.5% (flat vs. Q4 despite seasonality), operating margin 22.2%, EPS $0.56, and ~$2.4B cash with >$400M of FCF in the quarter.
Against a Q2'25 base of $1.157B (U.S. $841M, Intl $316M), the growth-rate math implies roughly:
| Reported growth | Implied Q2'26 revenue |
|---|---|
| +11% | ~$1.28B |
| +12% | ~$1.30B |
| +13% | ~$1.31B |
| +15% | ~$1.33B |
A few framing points: - The comp mix flips this quarter. Management flagged that U.S. comps are tougher in H1 (Q2'25 U.S. grew +15%) while international comps are easier in H1 (Q2'25 Intl +16% reported but only +14% organic, and Q1'26 Intl already ran +26% reported / +17% organic on easy comps like France and Canada). So expect the international line to keep carrying an outsized share of growth, with the U.S. number the more scrutinized figure. - FY guide midpoint ($5.205B) less Q1 ($1.192B) leaves ~$4.01B across Q2–Q4 — i.e., the full-year bar is very achievable, so the debate is about upside and mix, not whether they hit it. - Margin bias is to the upside. Q1 gross margin (63.5%) was already tracking above the low end of guide; management explicitly said they would have raised GM guidance if not for a 50–100 bps oil/resin/freight placeholder. If that geopolitical risk fades, watch for a gross-margin and/or operating-margin raise — a likely positive surprise vector.
1. U.S. new-patient starts / share — the swing factor. This has been the sore spot. For four-plus quarters management has used "close to a record" language for U.S. starts; Q1 was a global record but only "close to a record" in the U.S. Bears (and a competitor's commentary) have argued the U.S. CGM market is in a slower-growth phase absent new coverage/indications. DexCom's rebuttal: category penetration is only ~30% of covered lives, and they're now taking share in T2NIT. Any confirmation that U.S. starts hit an outright record — or a clean acceleration — would be the single most reassuring data point. Also listen for retention/utilization color (NPS is rising with 15-Day) since that, not just new starts, drives the active base.
2. G7 15-Day rollout. The launch is the near-term engine: better algorithm/accuracy, longer wear, higher NPS, plus a gross-margin tailwind. Management targets ~50% of the U.S. base converted by year-end and is now compatible with Tandem, Insulet and Beta Bionics. Watch for (a) conversion pace, (b) whether it's pulling in new customers vs. just converting the base, and (c) the H2 international 15-Day launch starting this half.
3. Type 2 non-insulin coverage — the multi-year story. - Commercial: The Prime Therapeutics win begins this summer, putting DexCom on track for >7M commercial T2NIT lives by year-end across the big PBMs. Look for the coverage figure to tick up and for commentary on how fast scripts follow (national formularies flip on ~immediately). - CMS/Medicare: The biggest catalyst. LRP conservatively models coverage kicking in mid-2027, but management says a decision could come anytime through end-2026 and that the RCT "may not be required." Any change in tone on CMS timing will move the stock. - CONNECT RCT: DexCom read out its pivotal T2NIT randomized controlled trial at ADA (June 6) — positioned as the "MOBILE/DIaMonD moment" for non-insulin. Expect management to lean on this data as the evidentiary anchor for global and Medicare coverage; investors will want to hear how payers/CMS are responding to it.
4. International. Expect this to remain the growth standout. Watch for updates on basal reimbursement wins OUS (currently only Japan/France), tender wins (portfolio approach now getting DexCom onto formerly-exclusive-competitor tenders), and the Stelo / Dexcom Flex international launches (Germany, Korea, Australia/NZ, UK).
5. Capital allocation & Elliott. DexCom is executing a $1B buyback fully in 2026 and committed to ≥50% of annual FCF to repurchases — management explicitly flagged a "disconnect" in the share price. With ~$2.4B cash and strong FCF, watch for buyback pace and any tuck-in M&A signaling. Also note Elliott Management helped add two operations/med-tech board directors and DexCom repurposed a board committee toward operations/innovation — activist involvement is a background dynamic worth tracking.
Useful context for how any Q2 datapoint gets interpreted: - 10%+ revenue growth every year through 2030 (not a CAGR — each year), with covered lives more than doubling from ~23M to ~52M. - Gross margin to high-60s, non-GAAP operating margin to 29–30%, adjusted EBITDA margin to 36–37% by 2030. - Pipeline: G8 (50% smaller, self-adapting sensor, ~10% cheaper to build, submission in 2027 / launch late-'27 or early-'28), plus multi-analyte (potassium), hospital CGM, and prediabetes/screening ambitions. - LRP already bakes in competitive bidding from 2028 and competitor launches — framed as conservative.
Bull case: U.S. starts inflect to a record; 15-Day conversion + margin execution drives a gross/operating-margin raise; CMS timing tone improves; buyback provides a floor. Given margin momentum, a guidance raise is a credible upside catalyst.
Bear case: U.S. starts are again only "close to a record," feeding the "U.S. market is decelerating" narrative; international strength (on easy comps) gets discounted as lower-quality/temporary; oil/resin pressure caps the margin raise; and with the stock already up ~13% YTD and near highs post-ADA/Investor Day, the bar for a positive reaction is high.
Financially, the quarter should be fine — the full-year bar is low and margins are trending favorably, so a modest revenue beat and a possible margin raise are the base case. The stock reaction will hinge on the U.S. new-patient/share narrative and any freshening of the CMS/T2NIT timeline, not the headline revenue. Watch the U.S. line, the 15-Day conversion pace, the covered-lives count, and management's CMS language most closely.
(Sources: DexCom Q1 2026 earnings call & release, Q2 2025 earnings release, May 14, 2026 Investor Day transcript, recent insider Form 144 filings, and DXCM daily price history. Note: consensus/Street estimates for Q2 2026 were not available in the tools accessed here, so the revenue table above is derived from the prior-year comp and company guidance rather than published analyst estimates.)